Research

May 10, 2022

Resistance to COVID-19 drug detected in lab study

Vanderbilt research shows that the virus that causes COVID-19 can develop partial resistance to the antiviral drug remdesivir during infection of cultured cells in the laboratory by more than one mechanism.  

By Bill Snyder
May 10, 2022

Autism and sleep problems

Vanderbilt researchers developed a framework for using de-identified medical records to characterize sleep in people on the autism spectrum — a framework that should also be useful for studying other neurodevelopmental disorders.

By Emily Stembridge
May 9, 2022

Gene variants and transplant drug dose

Genotyping multiple enzymes that metabolize the immunosuppressive drug tacrolimus — common used for lung transplant recipients — is important for correct dosing of the drug, Vanderbilt researchers found.

By Leigh MacMillan
Erin Green, PhD, Eric Skaar, PhD, MPH, and colleagues are studying how a certain bacterial pathogen can survive on hospital surfaces for months with no water.
May 5, 2022

VUMC team discovers how bacterial pathogen survives without water

Vanderbilt researchers are studying a bacterial pathogen that can survive on hospital surfaces — without water — for months, an ability that has helped it become a leading cause of hospital-acquired infections.

By Leigh MacMillan
May 5, 2022

COVID-associated bleeding risk

While case reports have noted acquired hemophilia after COVID-19 infection or vaccination, a new study finds no increased risk.

By Leigh MacMillan
May 5, 2022

Gene network linked to Type 2 diabetes

Vanderbilt researchers used a novel analytical approach to identify a network of genes associated with Type 2 diabetes, including 31 genes that had not previously been associated with the disease.

By Joshua Baker
April 28, 2022

Studies combine genetic testing, electronic health records to find undiagnosed diseases

Combining genetic testing with information from electronic health records revealed undiagnosed heart rhythm disorders and new conditions associated with inherited cancer gene mutations.
By Leigh MacMillan
April 26, 2022

Calculating risk for uterine fibroids

Vanderbilt researchers have constructed a polygenic risk score for uterine fibroids that will be useful for exploring causes of these benign tumors and identifying novel drug targets and therapies.
By Leigh MacMillan
April 25, 2022

Molecular testing across tumor types

The KRAS inhibitor sotorasib is newly approved for one kind of lung cancer; Vanderbilt researchers ask if it should be considered for another type if the tumor has the gene mutation it targets.
By Leigh MacMillan
April 21, 2022

VUMC a national leader in physician-scientist training

Physician-scientists from Vanderbilt University Medical Center were well represented at the recent annual meeting of the American Society for Clinical Investigation (ASCI), Association of American Physicians (AAP) and the American Physician-Scientist Association.
By Bill Snyder
April 21, 2022

When science spills onto social media

Vanderbilt researchers report that social media posts can offer insights into how the public feels about genome editing, with stances varying across platforms and differing from those of academics and policy makers.
By Paul Govern
April 21, 2022

Regev’s Discovery Lecture

Aviv Regev, PhD, recipient of the 2021 Vanderbilt Prize in Biomedical Science, gave her Vanderbilt Prize Discovery Lecture on April 14.
By Bill Snyder
April 21, 2022

Youthful healing for burn wounds

Topical treatment of burns with an immunosuppressive drug counteracted the negative effects of aging on wound healing, Vanderbilt researchers have discovered.
By Sarah E. Glass
1 … 36 37 38 39 40 … 125